Phase 1/2 trial of single-session stereotactic body radiotherapy for previously unirradiated spinal metastases.
Phase 1/2 trial of single-session stereotactic body radiotherapy for previously unirradiated spinal metastases.
复制标题
DOI：
10.1002/cncr.27530
复制
发表时间：
2012-10-15
期刊：
影响因子：
6.2
通讯作者：
Chang, Eric L.
中科院分区：
文献类型：
--
作者：
Garg, Amit K.;Shiu, Almon S.;Yang, James;Wang, Xin-Shelley;Allen, Pamela;Brown, Barry W.;Grossman, Patricia;Frija, Erik K.;McAleer, Mary Frances;Azeem, Syed;Brown, Paul D.;Rhines, Laurence D.;Chang, Eric L.
This Phase I/II study tests the hypothesis that single-fraction SBRT for previously un-irradiated spinal metastases is a safe, feasible, and efficacious treatment approach. All patients were evaluated by a multidisciplinary team. Spinal MRI was performed before treatment and at regular intervals to both define target volume and response to treatment. SBRT was delivered to a peripheral dose of 16–24 Gy in 1 fraction while limiting dose to the spinal cord. Higher doses were used for renal cell histology. The NCI Common Toxicity Criteria 2.0 and McCormick neurological function score were used as toxicity assessment tools. A total of 61 patients harboring 63 tumors of the non-cervical spine were enrolled and treated with SBRT between 2005 and 2010 on a prospective Phase I/II trial at the University of Texas M. D. Anderson Cancer Center. Mean follow-up was 20 months. Actuarial 18-month imaging local control for all patients was 88%. Actuarial 18-month overall survival for all patients was 64%. Median survival for all patients was 30 months. No significant differences in outcomes were noted with respect to tumor histology and SBRT dose. Two patients experienced radiation adverse events (Grade 3 or higher). Actuarial 18-month freedom from neurologic deterioration from any cause as was 82%. This Phase I/II data support an expanded indication for SBRT as first-line treatment of selected spinal metastases patients. Additional studies that can prospectively identify predictive factors for spinal cord toxicity after SBRT are warranted to minimize the incidence of this serious yet rare complication.
登录
查看更多内容
DOI：
10.1016/j.ijrobp.2010.08.021
发表时间：
2012-01-01
影响因子：
7
作者：
Sahgal, Arjun;Ma, Lijun;Larson, David A.
通讯作者：
Larson, David A.
影响因子：
6.2
作者：
Ryu, Samuel;Jin, Jian-Yue;Kim, Jae Ho
通讯作者：
Kim, Jae Ho
影响因子：
6.2
作者：
Garg, Amit K.;Wang, Xin-Shelley;Chang, Eric L.
通讯作者：
Chang, Eric L.
影响因子：
2.8
作者：
Moulding, Hugh D.;Elder, James B.;Bilsky, Mark H.
通讯作者：
Bilsky, Mark H.
影响因子：
4.1
作者：
MCCORMICK, PC;TORRES, R;STEIN, BM
通讯作者：
STEIN, BM